AnxietyPhase 4NCT02177955
Comparative Study of Hemodynamic Changes Caused by Diazepam and Midazolam During Third Molar Surgery
A Phase 4 study testing 7.5 mg Midazolam and 10 mg diazepam in people with Anxiety, run by Jimmy Barbalho at 1 site in Brazil.
Trial summary
Objective: The aim of the present study was to compare hemodynamic changes using 7.5 mg of midazolam and 10.0 mg of diazepam during the surgical removal of symmetrically positioned third molars. Read more about this study
- Who is it for?
- Ages 18 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Anxiety
- What is being tested?
- 7.5 mg Midazolam and 10 mg diazepam
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 120 participants
- Where
- 1 siteBrazil
- Study dates
- Jan 2011to Sep 2012
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- The inclusion criteria were classification in Group 1 of the American Society of Anesthesiology (normal healthy patient with no adverse systemic condition or continuous use of medication) and no self-reported reactions or allergies to the drugs employed in the study
Who cannot join
- The exclusion criteria were refusal to participate after reading the statement of informed consent, self-reported allergy to the drugs employed and failure to return for the second surgery on the contralateral side
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparative Study of Hemodynamic Changes Caused by Diazepam and Midazolam During Third Molar Surgery. A Prospective Randomized Study
Objective: The aim of the present study was to compare hemodynamic changes using 7.5 mg of midazolam and 10.0 mg of diazepam during the surgical removal of symmetrically positioned third molars.
Study design: A prospective, randomized, double-blind, clinical trial was carried out involving 120 patients divided in three groups: Group 1 (diazepam and placebo), Group 2 (midazolam and placebo) and Group 3 (diazepam and midazolam). Each subject underwent two surgeries on separate occasions under local anesthesia.
Read the detailed description
Study design A double-blind, randomized, crossover, clinical trial with a split-mouth design was carried out. This study received approval from the Human Research Ethics Committee of the institution at which it was carried out (process number: 001.0.097.000-08) and was conducted in compliance with the Consolidated Standards of Reporting Trials (CONSORT) statement. All patients signed a statement of informed consent agreeing to participate in the study.
Sample size and pilot study The sample size was estimated using the a computational program. Thirty patients were submitted to third molar surgeries in a pilot study to determine the sample size. This step was necessary due to the lack of similar studies in the literature. Calculations were performed with specific programs taking into consideration the variables, a 95% confidence interval, 80% test power and 5% error. At the end of the study, 120 patients were analyzed (40 in each group), totaling 240 surgeries.
Sample selection One hundred twenty eight individuals between 18 and 40 years of age were selected for participation in the present study and submission to maxillary and mandibular third molar extractions bilaterally at the Department of Oral-Maxillofacial Surgery. Each patient was to be submitted to two surgeries. The third molars (maxillary or mandibular) needed to have the same degree of impaction on both sides.
Three groups were formed: Group A received diazepam and placebo, Group B received midazolam and placebo and Group C received midazolam and diazepam. For the purposes of randomization and blinding of the surgeon and researcher in charge of analyzing the results, the groups were renominated Groups 1, 2 and 3. The randomization procedure was carried out by a researcher who was not directly involved in the surgeries or evaluations. Sequentially numbered, sealed, opaque envelopes were used, each containing a combination of substances and the side to be submitted to the first surgery. For each patient, the researcher opened an envelope, informed the main investigator and surgeon of the side to be operated, and administered the substance to the patient. The second surgery was performed on the contralateral side with the administration of the second substance. Blinding was performed to avoid awareness regarding what substance was administered in each surgery. For such, the pills were fabricated with the same outer color and a standardized size at the Pernambuco Pharmaceutical Laboratory (Brazil) and were packaged in recipients with the same color. The recipients were denominated 1, 2 and 3.
Surgical procedures and medications As the patients were classified as healthy, no prophylactic use of antibiotics was performed prior to surgery for the prevention of bacterial endocarditis, as recommended by the American Heart Association. All patients rinsed their mouths with 0.12% chlorhexidine for one minute prior to surgery to reduce the bacterial population in the oral cavity. Moreover, all patients were instructed to take two 4-mg pills of dexamethasone one hour prior to surgery. The use of a corticosteroid in the preoperative period minimizes the occurrence of postoperative swelling and reduces the risk of trismus.13 The substances (diazepam, midazolam and placebo) were administered orally 45 minutes prior to the surgical procedure. As the substances were masked, neither the surgeon nor the patient was aware of what substance was given (double-blind study).
- Conditions
- Anxiety
- Being tested
- 7.5 mg Midazolam, 10 mg diazepam
- Keywords
- Third Molar, Anty-anxiety drugs, hemodynamic, Benzodiazepines
- Medical subject headings
- Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
7.5 mg MidazolamDrug
7.5 mg midazolam 45 minutes before surgery
10 mg diazepamDrug
10 mg midazolam 45 minutes before surgery
| Study group | Role | What they receive |
|---|---|---|
| midazolan | Placebo comparator | 7.5 mg midazolan 45 minutes before the surgery Receives: Drug: 7.5 mg Midazolam |
| diazepam | Placebo comparator | 10 mg diazepam 45 minutes before the surgery Receives: Drug: 10 mg diazepam |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes from baseline in systolic blood pressure until the end of surgery
Measured: baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery.
Changes from baseline in diastolic blood pressure until the end of surgery
Measured: Baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery
Changes from baseline in mean blood pressure until the end of surgery
Measured: Baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery
Changes from baseline in heart rate until the end of surgery
Measured: Baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery
Changes from baseline in rate pressure product until the end of surgery
The rate pressure is the product of the multiplication of systolic blood pressure by heart rate
Measured: Baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery
Changes from baseline in oxygen saturation until the end of surgery
Measured: Baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery
Change from baseline in pressure rate quotient until the end of surgery
Pressure rate quotient is calculated by dividing mean blood pressure by heart rate
Measured: Baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jun 2014 (estimated)
- Study startJan 2011
- Primary completionJul 2012
- Study completionSep 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AnxietyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 120 participants (actual)
Sponsor and investigators
- Lead sponsor
- Jimmy Barbalho
- Sponsor type
- University, hospital or other
- Collaborators
- University of Pernambuco
- Responsible party
- Sponsor-investigator, Jimmy Barbalho, University of Pernambuco
- Investigators
- Hécio H De Morais, PhD, Principal investigator, University of Pernambuco
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02177955
- Sponsor's protocol ID
- 001.0.097.000-08
- Other IDs
- 001.0.097.000-08
- Status last verified
- Jun 2014
- First submitted
- 21 Jun 2014
- Last updated
- 30 Jun 2014
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 30 Jun 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Study of Hemodynamic Changes Caused by Diazepam and Midazolam During Third Molar Surgery. A Prospective Randomized Study
- ClinicalTrials.gov ID
- NCT02177955
- Acronym / sponsor ID
- 001.0.097.000-08
- Conditions
- Anxiety
- Keywords
- Third Molar, Anty-anxiety drugs, hemodynamic, Benzodiazepines
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 120 participants (actual)
- Lead sponsor
- Jimmy BarbalhoUniversity, hospital or other
- Collaborators
- University of Pernambuco
- Study start
- Jan 2011
- Primary completion
- Jul 2012 (actual)
- Study completion
- Sep 2012 (actual)
- First posted
- 30 Jun 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Objective: The aim of the present study was to compare hemodynamic changes using 7.5 mg of midazolam and 10.0 mg of diazepam during the surgical removal of symmetrically positioned third molars.
Study design: A prospective, randomized, double-blind, clinical trial was carried out involving 120 patients divided in three groups: Group 1 (diazepam and placebo), Group 2 (midazolam and placebo) and Group 3 (diazepam and midazolam). Each subject underwent two surgeries on separate occasions under local anesthesia.
Detailed description
Study design A double-blind, randomized, crossover, clinical trial with a split-mouth design was carried out. This study received approval from the Human Research Ethics Committee of the institution at which it was carried out (process number: 001.0.097.000-08) and was conducted in compliance with the Consolidated Standards of Reporting Trials (CONSORT) statement. All patients signed a statement of informed consent agreeing to participate in the study.
Sample size and pilot study The sample size was estimated using the a computational program. Thirty patients were submitted to third molar surgeries in a pilot study to determine the sample size. This step was necessary due to the lack of similar studies in the literature. Calculations were performed with specific programs taking into consideration the variables, a 95% confidence interval, 80% test power and 5% error. At the end of the study, 120 patients were analyzed (40 in each group), totaling 240 surgeries.
Sample selection One hundred twenty eight individuals between 18 and 40 years of age were selected for participation in the present study and submission to maxillary and mandibular third molar extractions bilaterally at the Department of Oral-Maxillofacial Surgery. Each patient was to be submitted to two surgeries. The third molars (maxillary or mandibular) needed to have the same degree of impaction on both sides.
Three groups were formed: Group A received diazepam and placebo, Group B received midazolam and placebo and Group C received midazolam and diazepam. For the purposes of randomization and blinding of the surgeon and researcher in charge of analyzing the results, the groups were renominated Groups 1, 2 and 3. The randomization procedure was carried out by a researcher who was not directly involved in the surgeries or evaluations. Sequentially numbered, sealed, opaque envelopes were used, each containing a combination of substances and the side to be submitted to the first surgery. For each patient, the researcher opened an envelope, informed the main investigator and surgeon of the side to be operated, and administered the substance to the patient. The second surgery was performed on the contralateral side with the administration of the second substance. Blinding was performed to avoid awareness regarding what substance was administered in each surgery. For such, the pills were fabricated with the same outer color and a standardized size at the Pernambuco Pharmaceutical Laboratory (Brazil) and were packaged in recipients with the same color. The recipients were denominated 1, 2 and 3.
Surgical procedures and medications As the patients were classified as healthy, no prophylactic use of antibiotics was performed prior to surgery for the prevention of bacterial endocarditis, as recommended by the American Heart Association. All patients rinsed their mouths with 0.12% chlorhexidine for one minute prior to surgery to reduce the bacterial population in the oral cavity. Moreover, all patients were instructed to take two 4-mg pills of dexamethasone one hour prior to surgery. The use of a corticosteroid in the preoperative period minimizes the occurrence of postoperative swelling and reduces the risk of trismus.13 The substances (diazepam, midazolam and placebo) were administered orally 45 minutes prior to the surgical procedure. As the substances were masked, neither the surgeon nor the patient was aware of what substance was given (double-blind study).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| midazolan | Placebo comparator | Drug: 7.5 mg Midazolam7.5 mg midazolan 45 minutes before the surgery |
| diazepam | Placebo comparator | Drug: 10 mg diazepam10 mg diazepam 45 minutes before the surgery |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- The inclusion criteria were classification in Group 1 of the American Society of Anesthesiology (normal healthy patient with no adverse systemic condition or continuous use of medication) and no self-reported reactions or allergies to the drugs employed in the study
Key exclusion criteria (1 listed)
- The exclusion criteria were refusal to participate after reading the statement of informed consent, self-reported allergy to the drugs employed and failure to return for the second surgery on the contralateral side
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 7.5 mg Midazolam7.5 mg midazolam 45 minutes before surgery | Drug | midazolan |
| 10 mg diazepam10 mg midazolam 45 minutes before surgery | Drug | diazepam |
Primary outcome
Changes from baseline in systolic blood pressure until the end of surgery
Time frame: baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery.
Changes from baseline in diastolic blood pressure until the end of surgery
Time frame: Baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery
Changes from baseline in mean blood pressure until the end of surgery
Time frame: Baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery
Changes from baseline in heart rate until the end of surgery
Time frame: Baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery
Changes from baseline in rate pressure product until the end of surgery
Time frame: Baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery
The rate pressure is the product of the multiplication of systolic blood pressure by heart rate
Changes from baseline in oxygen saturation until the end of surgery
Time frame: Baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery
Change from baseline in pressure rate quotient until the end of surgery
Time frame: Baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery
Pressure rate quotient is calculated by dividing mean blood pressure by heart rate
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jun 2014.
- Related InfoLink provided by the sponsor.
Related trials for Anxiety
Active, not recruiting
Supporting Health in Veterans With Heart Failure
Heart Failure
Active, not recruiting
Targeting Social Function in Anxiety and Eating Disorders
Eating Disorders, Anorexia Nervosa
Recruiting
Modulating Escape Using Focused Ultrasound
Anxiety Disorders
RecruitingPhase 1
Open-Label Psilocybin Study in Transdiagnostic Population
Transdiagnostic, Depression - Major Depressive Disorder
RecruitingObservational study
Sensory Profile of People With High Intellectual Potential (HIP)
High Intellectual Potential
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hécio H De Morais, PhD principal investigator
University of Pernambuco
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing 7.5 mg Midazolam and 10 mg diazepam in people with Anxiety, run by Jimmy Barbalho at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Jun 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes from baseline in systolic blood pressure until the end of surgery (time frame: baseline, 2 minutes, 7 minutes, 12 minutes, end of surgery.). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jun 2014; AzTrials last refreshed its copy on 1 Nov 2026.